What Factors Propelled The Growth Of The Gestational Diabetes Market In The Past?
The gestational diabetes market has seen considerable growth due to a variety of factors.
• In recent times, the market size for gestational diabetes has seen considerable growth. It is projected to escalate from $8.37 billion in 2024 to approx $9.14 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%.
The considerable growth during the previous period can be ascribed to the increased risk of diabetes, enhanced accuracy in blood glucose level measurement, augmented count of insurance providers, and an overall growth in the diabetic patient population.
What is the Market Size Forecast for the Gestational Diabetes Market?
The gestational diabetes market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for gestational diabetes is predicted to experience a robust increase in the coming years, growing to $12.90 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%.
The projected growth during this period can be traced to various factors such as the high rate of obesity, widespread acceptance of cloud-based project structures, and the growing use of related technology and applications, as well as the surge in diabetes due to unhealthy lifestyle choices. Other factors include the augmentation in public health awareness and the escalating prevalence of diabetes. Key trends throughout this period are expected to include digital applications for diabetes management, closed-loop control systems, diabetes management technological advances, enzymatic technology, and innovative medical technologies.
Which Factors Are Boosting Growth In The Gestational Diabetes Market?
The escalating number of obese individuals is predicted to spur the advancement of the gestational diabetes market. The term "obese population" refers to individuals with a body mass index (BMI) of 30 or above, suggestive of an excessively high amount of body fat, presenting considerable health risks. The increasing prevalence of obesity is due to factors such as a lack of physical activity, an increased intake of high-calorie, processed foods, genetic factors, and limited healthy food and exercise options. It is integral to treat gestational diabetes in the obese population due to their higher susceptibility to insulin resistance and excessive weight gain during pregnancy which, if left untreated, may result in complications for the mother and child. For instance, data from the World Health Organization, based in Switzerland, from March 2024 revealed that about one in eight people worldwide were classified as obese in 2022. This included 2.5 billion adults over the age of 18 who were considered overweight, with 890 million of them suffering from obesity. In the adult population, 43% were overweight, with 16% classified as obese. It also indicated that 37 million under-five children were overweight, and over 390 million children and adolescents aged between 5 and19 years were categorized as overweight, with 160 million of them suffering from obesity. Thus, the rising obese population is fueling the growth of the gestational diabetes market.
What Are The Major Segments Within The Gestational Diabetes Market?
The gestational diabetes market covered in this report is segmented –
1) By Types: Type A1, Type A2, Other Types
2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological treatment
3) By Administration: Oral, Intravenous, Other Administrations
4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers
Subsegments:
1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes
2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes
3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications
Pre-Book The Gestational Diabetes Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Gestational Diabetes Market?
In an effort to provide prompt and reliable methods for early detection of gestational diabetes, dominant firms in the gestational diabetes market are concentrating on creating technologically sophisticated products such as gestational diabetes diagnostic kits. This kind of kit is a healthcare instrument designed to determine blood sugar levels and recognize abnormal glucose tolerance in expectant women, assisting in the early diagnosis and management of the disease. For example, DirectSens GmbH, a biotech firm headquartered in Austria, introduced the XpressGT RUO kit in August 2024. The kit is designed to diagnose conditions like gestational diabetes, endometriosis, insulin resistance, and liver disease by accurately measuring the levels of 2-hydroxybutyrate (2-HB) in venous blood, a byproduct of the liver's normal functioning. High 2-HB levels are linked to heightened reductive stress, which in turn is related to various endocrine and obesity-related issues including insulin resistance. The kit can be used with any existing clinical analyzer and provides results in a mere 8 minutes, making it a quick and effective diagnostic tool.
Who Are the Key Players in the Gestational Diabetes Market?
Major companies operating in the gestational diabetes market are include:
• Sanofi S.A.
• AstraZeneca plc
• Abbott Laboratories
• Eli Lilly and Company
• Novo Nordisk A/S
• Becton
• Dickinson and Company
• Boehringer Ingelheim GmbH
• Dexcom Inc
• Biocon Limited
• LifeScan Inc
• Ascensia Diabetes Care Holdings AG
• Trividia Health Inc.
• Nipro Diagnostics
• Inc.
• Sernova Corp.
• ZyVersa Therapeutics
• Inc.
• Peptron Inc.
• Roche Diabetes Care
• DiabetOmics Inc
• Merck & Co. Inc.
• Medtronic plc
What Is The Most Dominant Region In The Gestational Diabetes Market?
North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
